Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 10/20 | 0.36 |
| ▸ | RXRB | P28702 | 9/20 | 0.36 |
| ▸ | RXRG | P48443 | 6/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | CBFB | Q13951 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632672 | 0.82 | CBFB (0.34) | ALDH1A1HPGDHTTSMN1; SMN2RIPK2 | |
| SCHEMBL27033804 | 0.82 | RXRA (0.38) | RXRARXRBRXRGTLR7PLAU | |
| SCHEMBL26686001 | 0.80 | HSD17B10 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL30632868 | 0.80 | HSD17B10 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL30632645 | 0.76 | ALDH1A1 (0.33) | CNR1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL17581149 | 0.74 | RIPK2 (0.38) | RXRARXRBRXRGRIPK2TLR7 | |
| SCHEMBL30756555 | 0.73 | S1PR2 (0.35) | CNR1ALDH1A1HPGDHTTSMN1; SMN2 | |
| SCHEMBL30809049 | 0.69 | HRH4 (0.35) | SMN1; SMN2 | |
| SCHEMBL113146 | 0.69 | HRH4 (0.35) | SMN1; SMN2 | |
| SCHEMBL28803013 | 0.69 | RXRA (0.39) | RXRARXRBRXRGALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | RXRA 3442/4885RXRB 2714/4885RXRG 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.